Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis
- PMID: 17627679
- DOI: 10.1111/j.1479-828X.2007.00736.x
Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis
Abstract
Recurrent vulvovaginal candidiasis (VVC) is a condition what causes women a great deal of discomfort, inconvenience, and sometimes has psychological sequelae.(1) This condition is notoriously difficult to manage. Conventional management is generally favoured by medical practitioners. Some practitioners prefer not to offer other options because of significant possible side-effects and the lack of research supporting alternative treatments. There are many studies and much available information surrounding uncomplicated VVC, including two systematic reviews.(2,3) In the area of recurrent VVC however, quality conclusive studies are scarce, and recurrent VVC is featured infrequently in randomised controlled trials (RCTs). Systematic reviews that strongly support a particular pharmacological method of conventional management of recurrent VVC over another are absent from medical literature. Recommendations are largely formed on the basis of scanty RCTs and expert opinion. There is even less conclusive evidence in the area of alternative therapies; yet despite this, anecdotally many practitioners (both alternative and mainstream) continue to advocate certain treatments in the absence of any reliable cure that can be confidently prescribed. As the use of methods other than mainstream medicine becomes more widespread, it is important to be aware of both conventional and non-conventional management of recurrent vulvovaginal candidiasis. Practitioners need to ascertain their patient's preference and treatment history. It is difficult to find comprehensive literature assessing both approaches. Giving women the most up-to-date and relevant information, and different management options, is essential in allowing them to make informed decisions. This review critically assesses both mainstream and less conventional approaches in the management of recurrent VVC.
Similar articles
-
Probiotics for prevention of recurrent vulvovaginal candidiasis: a review.J Antimicrob Chemother. 2006 Aug;58(2):266-72. doi: 10.1093/jac/dkl246. Epub 2006 Jun 21. J Antimicrob Chemother. 2006. PMID: 16790461 Review.
-
Vulvovaginal candidiasis: a current update.Nurse Pract Forum. 1992 Sep;3(3):135-44. Nurse Pract Forum. 1992. PMID: 1472885
-
Recurrent vulvovaginitis candidiasis; an overview of traditional and alternative therapies.Adv Nurse Pract. 2005 May;13(5):24-9; quiz 30. Adv Nurse Pract. 2005. PMID: 15898312 Review.
-
Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence.J Womens Health (Larchmt). 2011 Aug;20(8):1245-55. doi: 10.1089/jwh.2010.2708. Epub 2011 Jul 20. J Womens Health (Larchmt). 2011. PMID: 21774671 Review.
-
Recurrent vulvovaginal candidiasis.Aust Fam Physician. 2005 Mar;34(3):147-50. Aust Fam Physician. 2005. PMID: 15799663 Review.
Cited by
-
Deciphering the role of female reproductive tract microbiome in reproductive health: a review.Front Cell Infect Microbiol. 2024 Mar 18;14:1351540. doi: 10.3389/fcimb.2024.1351540. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38562966 Free PMC article. Review.
-
Vaginal microbiota: Potential targets for vulvovaginal candidiasis infection.Heliyon. 2024 Mar 2;10(5):e27239. doi: 10.1016/j.heliyon.2024.e27239. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38463778 Free PMC article. Review.
-
Treatment for recurrent vulvovaginal candidiasis (thrush).Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD009151. doi: 10.1002/14651858.CD009151.pub2. Cochrane Database Syst Rev. 2022. PMID: 35005777 Free PMC article. Review.
-
Vulvovaginal Candidosis: Current Concepts, Challenges and Perspectives.J Fungi (Basel). 2020 Nov 7;6(4):267. doi: 10.3390/jof6040267. J Fungi (Basel). 2020. PMID: 33171784 Free PMC article. Review.
-
Formulation, Pharmacological Evaluation, and Efficacy Studies of Occidiofungin, a Novel Antifungal.Antimicrob Agents Chemother. 2020 Nov 17;64(12):e01737-20. doi: 10.1128/AAC.01737-20. Print 2020 Nov 17. Antimicrob Agents Chemother. 2020. PMID: 32958713 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials